Log in

OTCMKTS:MKGAFMerck KGaA Stock Price, Forecast & News

$119.30
+1.80 (+1.53 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$119.10
Now: $119.30▼
$119.50
50-Day Range
$107.95
MA: $114.95▼
$121.10
52-Week Range
$82.00
Now: $119.30▼
$134.00
Volume241 shs
Average Volume714 shs
Market Capitalization$15.42 billion
P/E Ratio20.22
Dividend YieldN/A
Beta0.77
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.71 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MKGAF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.merckgroup.com
Phone49-61-517-20

Debt

Debt-to-Equity Ratio0.55
Current Ratio0.93
Quick Ratio0.61

Price-To-Earnings

Trailing P/E Ratio20.22
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$18.09 billion
Price / Sales0.85
Cash Flow$37.75 per share
Price / Cash Flow3.16
Book Value$155.24 per share
Price / Book0.77

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$1.48 billion
Net Margins9.49%
Return on Equity12.44%
Return on Assets5.28%

Miscellaneous

Employees57,071
Outstanding Shares129,240,000
Market Cap$15.42 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable
OTC:MKGAF Rates by TradingView

Receive MKGAF News and Ratings via Email

Sign-up to receive the latest news and ratings for MKGAF and its competitors with MarketBeat's FREE daily newsletter.

Merck KGaA (OTCMKTS:MKGAF) Frequently Asked Questions

How has Merck KGaA's stock been impacted by COVID-19 (Coronavirus)?

Merck KGaA's stock was trading at $111.2250 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MKGAF shares have increased by 7.3% and is now trading at $119.30. View which stocks have been most impacted by Coronavirus.

When is Merck KGaA's next earnings date?

Merck KGaA is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Merck KGaA.

How were Merck KGaA's earnings last quarter?

Merck KGaA (OTCMKTS:MKGAF) announced its quarterly earnings data on Thursday, May, 14th. The company reported $1.66 EPS for the quarter. The business earned $4.82 billion during the quarter. Merck KGaA had a net margin of 9.49% and a return on equity of 12.44%. View Merck KGaA's earnings history.

Has Merck KGaA been receiving favorable news coverage?

Headlines about MKGAF stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck KGaA earned a news impact score of -2.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Merck KGaA.

Who are some of Merck KGaA's key competitors?

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the following people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
  • Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
  • Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
  • Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the OTCMKTS under the ticker symbol "MKGAF."

How do I buy shares of Merck KGaA?

Shares of MKGAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck KGaA's stock price today?

One share of MKGAF stock can currently be purchased for approximately $119.30.

How big of a company is Merck KGaA?

Merck KGaA has a market capitalization of $15.42 billion and generates $18.09 billion in revenue each year. Merck KGaA employs 57,071 workers across the globe.

What is Merck KGaA's official website?

The official website for Merck KGaA is www.merckgroup.com.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, Darmstadt 2M, 64293. The company can be reached via phone at 49-61-517-20 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.